Last hope? new combo targets myeloma that resists standard drugs

NCT ID NCT01053949

Completed Disease control Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial tested a combination of pomalidomide and dexamethasone in 84 patients with advanced multiple myeloma whose cancer had worsened despite treatment with bortezomib and lenalidomide. The goal was to see if this drug pair could shrink tumors and control the disease. Researchers also compared two different dosing schedules to find the safest and most effective approach.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pomalidomide and dexamethasone
What this could lead to: If successful, this could provide a new treatment option for multiple myeloma patients who have not responded to other therapies.
What could go wrong: This is a phase II trial with only 84 participants, so results may not apply broadly. The drug combination may cause side effects and may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

CHRU-Hôpital Sud, avenue Laennec,

Amiens, 80054, France
Hématologie Clinique, CHU, Hôpital d'Enfants

Dijon, 21000, France
Hématologie Clinique, Hôpital Robert Debré, CHU Reims

Reims, 51092, France
Hématologie, CHRU, Hôpital A.Michallon

Grenoble, 38043, France
Hématologie, CHRU, Hôpital Purpan

Toulouse, 31059, France
Hématologie, CHRU, Hôpitaux de Brabois

Nancy, 54511, France
Hématologie, CHU, avenue G.Clemenceau

Caen, 14033, France
Hématologie, Hôpital Avicenne

Bobigny, 93009, France
Hématologie, Institut Paoli Calmette

Marseille, 13273, France
Hôpital Edouard HERRIOT

Lyon, 69437, France
Hôpital PONTCHAILLOU, CHU de RENNES

Rennes, 35033, France
Maladies du Sang, CHRU, Hôtel Dieu

Nantes, 44035, France
Maladies du Sang, CHU - Hôpital St Antoine

Paris, 75571, France
Médecine Interne, CHRU, Hôpital Sud

Rennes, 35056, France
Onco-Hématologie, CHRU- Hôpital Bretonneau

Tours, 37044, France
Service Immuno-Hématologie, Hôpital Saint-Louis

Paris, 75475, France
Service d'Hématologie, Centre Hospitalier Lyon Sud

Pierre-Bénite, 69495, France
Service des Maladies du Sang, CHRU

Lille, 59037, France
Service des Maladies du Sang, Hôpital Haut-Levèque

Pessac, 33604, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.